Harvard Bioscience

Yahoo Finance • 2 months ago

Harvard Bioscience, Inc. Q4 2025 Earnings Call Summary

Harvard Bioscience, Inc. Q4 2025 Earnings Call Summary - Moby Strategic Evolution and Operational Foundation Management characterized 2025 as a pivotal foundation-building year, focusing on improving financial flexibility and clarifying... Full story

Yahoo Finance • 2 months ago

Harvard Bioscience (HBIO) Earnings Transcript

Image source: The Motley Fool. DATE Mar. 12, 2026 at 8 a.m. ET CALL PARTICIPANTS President and Chief Executive Officer — John Duke Chief Financial Officer — Mark Frost Need a quote from a Motley Fool analyst? Email pr@fool.com Full C... Full story

Yahoo Finance • 2 months ago

Harvard Bioscience Sets 1-for-10 Reverse Stock Split; Shares Drop 12% Overnight

(RTTNews) - Harvard Bioscience, Inc. (HBIO), a provider of specialized life-science research instruments, announced for a 1-for-10 reverse stock split that will take effect on March 13, 2026, with split-adjusted trading beginning March 16,... Full story

Yahoo Finance • 2 months ago

Harvard Bioscience Announces Reverse Stock Split

Harvard Bioscience, Inc. Harvard Bioscience’s common stock is expected to begin trading on a post-split adjusted basis on March 16, 2026 HOLLISTON, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “C... Full story

Yahoo Finance • 6 months ago

Harvard Bioscience targets $22.5M–$24.5M Q4 revenue as backlog reaches two-year high, expanding product rollouts and distribution

Earnings Call Insights: Harvard Bioscience (HBIO) Q3 2025 MANAGEMENT VIEW * John Duke, President and CEO, reported operational progress and improvements across key areas, stating the company delivered revenue of $20.6 million, which wa... Full story

Yahoo Finance • 9 months ago

Judge orders Trump administration to restore part of UCLA's suspended funding

By Kanishka Singh and Nate Raymond WASHINGTON (Reuters) -A U.S. judge on Tuesday ordered President Donald Trump’s administration to restore a part of the federal grant funding that it recently suspended for the University of California, L... Full story

Yahoo Finance • 9 months ago

Harvard Bioscience outlines $19M–$21M Q3 revenue target as debt refinancing advances and product adoption accelerates

Earnings Call Insights: Harvard Bioscience (HBIO) Q2 2025 MANAGEMENT VIEW * John Duke, President and CEO, shared his initial observations as the new leader, stating he is "encouraged" by the company's operating team, innovation pipelin... Full story

Yahoo Finance • 9 months ago

Harvard Bioscience Inc (NASDAQ:HBIO) Reports Mixed Q2 2025 Earnings Amid Revenue Miss and Improved Cash Flow

Harvard Bioscience Inc (NASDAQ:HBIO [https://www.chartmill.com/stock/quote/HBIO/profile]) reported its second-quarter 2025 financial results, delivering mixed performance relative to analyst expectations. The company posted revenue of $20.... Full story

Yahoo Finance • 10 months ago

Harvard Bioscience stock holds Speculative Buy rating at Benchmark

Investing.com - Harvard Bioscience Inc. (NASDAQ:HBIO) has pre-announced second-quarter revenue of approximately $20.4 million, exceeding consensus expectations of $18.8 million, according to Benchmark. The company, currently trading at $0.... Full story

Yahoo Finance • 10 months ago

Harvard Bioscience announces CEO succession plan

* Harvard Bioscience (NASDAQ:HBIO [https://seekingalpha.com/symbol/HBIO]) announced [https://seekingalpha.com/pr/20169109-harvard-bioscience-announces-ceo-succession-plan-and-appointment-of-two-new-independent] a CEO succession plan unde... Full story

Yahoo Finance • 10 months ago

Harvard Bioscience names John Duke as new CEO as Jim Green retires

HOLLISTON, Mass. - Harvard Bioscience, Inc. (NASDAQ:HBIO) announced Thursday that board member John Duke will succeed Jim Green as President and CEO effective July 28, 2025, following Green’s planned retirement after more than eight years... Full story

Yahoo Finance • 10 months ago

Harvard Bioscience Announces CEO Succession Plan & Appointment of Two New Independent Directors to Board

Current Board member John Duke to succeed Jim Green as President & CEO Rob Gagnon and Seth Benson appointed as new Board membersQ2 ’25 revenue anticipated to be $20.4 million and Company reiterates previously announced Q2 ‘25 gross margin... Full story

Yahoo Finance • 11 months ago

Harvard Bioscience Appoints John Duke to Board of Directors

HOLLISTON, Mass., June 02, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced the appointment of John Duke to its board of directors, effective June 2, 2025. Mr. Duke will also serve on the a... Full story

Yahoo Finance • last year

Harvard Bioscience Schedules First Quarter 2025 Earnings Conference Call for May 12, 2025 at 8:00 AM ET

HOLLISTON, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended March 31, 2025, before the market opens on May 12, 2025, and will hold a conference call... Full story

Yahoo Finance • last year

Harvard Bioscience Announces CFO Transition

HOLLISTON, Mass., April 10, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced the resignation of Jennifer Cote, the Company’s Chief Financial Officer and Treasurer. Ms. Cote’s resignation wi... Full story

Yahoo Finance • last year

Harvard Bioscience, Inc. to Participate in Two Investor Conferences in March 2025

HOLLISTON, Mass., March 12, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that Jim Green, Chairman and Chief Executive Officer, and Jennifer Cote, Chief Financial Officer, will participate in two invest... Full story

Yahoo Finance • last year

Harvard Bioscience Announces Fourth Quarter and Full-Year 2024 Financial Results

HOLLISTON, Mass., March 12, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial results for the fourth quarter and full year ended December 31, 2024. Jim Green, Chairman and CEO, sa... Full story

Yahoo Finance • last year

Harvard Bioscience to Showcase Latest Solutions for Preclinical and Organoid Applications at Society of Toxicology Meeting

HOLLISTON, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that it will be showcasing its latest product innovations at the Society of Toxicology (SOT) conference from March 17-20, 2025, i... Full story

Yahoo Finance • last year

Harvard Bioscience Schedules Fourth Quarter 2024 Earnings Conference Call for March 12, 2025 at 8:00 AM ET

HOLLISTON, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended December 31, 2024, before the market opens on March 12, 2025, and will hold a conferenc... Full story

Yahoo Finance • 2 years ago

Harvard Bioscience to Present at Benchmark Company’s Discovery One-On-One Investor Conference on December 7, 2023

HOLLISTON, Mass., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced it will be presenting at the Benchmark Company 12th Annual Discovery One-on-One Investor Conference to be held Thursday December... Full story